According to findings of a phase III trial, which will be published in the The Lancet Oncology next month, 75% of the patients using palonosetron did not experience nausea and vomiting in the 24 hours immediately after receiving a chemotherapy regimen. And almost 57% of those on palonosetron avoided the ill effects during the first five days after treatment, compared with about 44% who had been given the standard granisetron medication.